Neurocrine Biosciences, Inc. (FRA:NB3)
Germany · Delayed Price · Currency is EUR | Market Cap | 12.96B +8.5% |
| Revenue (ttm) | 2.95B +34.4% |
| Net Income | 617.52M +102.6% |
| EPS | 5.97 +101.2% |
| Shares Out | n/a |
| PE Ratio | 20.99 |
| Forward PE | 12.30 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 131.30 |
| Previous Close | 129.35 |
| Day's Range | 131.30 - 131.30 |
| 52-Week Range | 102.55 - 160.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Neurocrine Biosciences
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical develo... [Read more]
Financial Performance
In 2025, Neurocrine Biosciences's revenue was $2.86 billion, an increase of 21.45% compared to the previous year's $2.36 billion. Earnings were $478.60 million, an increase of 40.23%.
Financial numbers in USD Financial StatementsNews
Neurocrine Biosciences Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and AI are reshaping R&D and operational strategies, while Medicare policy changes will impact pricing and revenue for key products. Growth is driven by strong commercial performance in CRENESSITY and VYKAT XR, with a robust pipeline targeting new indications and therapeutic areas.
Neurocrine price target raised to $183 from $182 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $183 from $182 and keeps an Equal Weight rating on the shares. The firm identifies NBIP-2118 in obesity as…
Neurocrine Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company has evolved into a multi-product enterprise with strong sales, a broad pipeline, and robust growth for INGREZZA, CRENESSITY, and VYKAT XR. Strategic investments, expanding market access, and upcoming late-stage pipeline readouts are expected to drive future growth despite anticipated pricing headwinds.
Neurocrine Biosciences Transcript: Wells Fargo 21st Annual Healthcare Conference
Quarterly revenue reached $1 billion, driven by strong growth in Ingrezza, CRENESSITY, and VYKAT XR. Ingrezza maintains double-digit growth with significant market headroom, while CRENESSITY's launch exceeded expectations and VYKAT XR integration is progressing. Major pipeline catalysts are expected in 2027–2028.
Neurocrine price target raised to $253 from $249 at Citi
Citi raised the firm’s price target on Neurocrine (NBIX) to $253 from $249 and keeps a Buy rating on the shares. Citi’s endocrinologist survey supports continued growth for Crenessity, the…
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its executives will participate at the following investor conferences: Wells Fargo 21 st Annua...
Neurocrine announces INECT-PRO Phase 4 open-label study results
Neurocrine (NBIX) Biosciences announced publication of the KINECT-PRO Phase 4 open-label study results demonstrating that treatment with once-daily INGREZZA, or valbenazine, capsules resulted in subst...
Neurocrine price target lowered to $165 from $190 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Neurocrine (NBIX) to $165 from $190 and keeps a Hold rating on the shares. The firm believes the Vykat commercial launch is…
Neurocrine price target lowered to $182 from $196 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Neurocrine (NBIX) to $182 from $196 and keeps an Equal Weight rating on the shares.
Neurocrine price target lowered to $218 from $221 at Bernstein
Bernstein lowered the firm’s price target on Neurocrine (NBIX) to $218 from $221 and keeps an Outperform rating on the shares. The firm notes Neurocrine reported promising Q2 earnings. Bernstein…
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
INGREZZA is the only vesicular monoamine transporter 2 inhibitor with clinical trial data demonstrating improvements in quality of life and functionality in people living with tardive dyskinesia acros...
Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug
Experts in Prader-Willi Syndrome on Tuesday raised safety concerns over Neurocrine's drug Vykat XR, citing serious adverse events reported in patients with the rare genetic disorder.
Neurocrine initiates Phase 1 study of NBIP-‘1968
Neurocrine (NBIX) Biosciences announced the initiation of a Phase 1 first-in-human clinical study evaluating the safety and tolerability of NBIP-‘1968, an investigational GLP-1/GIP/glucagon receptor t...
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Initiation of study marks an important milestone in advancing Neurocrine's obesity portfolio and investigational metabolic disease pipeline SAN DIEGO, Aug. 7, 2026 /PRNewswire/ -- Neurocrine Bioscie...
Neurocrine price target raised to $194 from $185 at Wedbush
Wedbush raised the firm’s price target on Neurocrine (NBIX) to $194 from $185 and keeps an Outperform rating on the shares. The Q2 quarterly report reflected strength across multiple products…
Neurocrine price target raised to $210 from $200 at Canaccord
Canaccord analyst Sumant Kulkarni raised the firm’s price target on Neurocrine (NBIX) to $210 from $200 and keeps a Buy rating on the shares. The firm said they are encouraged…
Neurocrine price target raised to $249 from $246 at Citi
Citi analyst Yigal Nochomovitz raised the firm’s price target on Neurocrine (NBIX) to $249 from $246 and keeps a Buy rating on the shares. After Q2 earnings, the firm raised…
Wells Fargo recommends buying Neurocrine on weakness after solid quarter
Wells Fargo thinks Neurocrine (NBIX) stock’s weakness today despite a “solid beat and raise quarter” last night is “overdone.” Fundamentals improved on EPS and Vykat commentary was not out of…
Neurocrine price target raised to $196 from $193 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Neurocrine (NBIX) to $196 from $193 and keeps an Equal Weight rating on the shares.
Neurocrine price target raised to $220 from $200 at TD Cowen
TD Cowen analyst Phil Nadeau raised the firm’s price target on Neurocrine (NBIX) to $220 from $200 and keeps a Buy rating on the shares. The firm said they delivered…
Neurocrine price target raised to $190 from $170 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Neurocrine (NBIX) to $190 from $170 and keeps a Hold rating on the shares.
Neurocrine price target raised to $214 from $199 at BofA
BofA raised the firm’s price target on Neurocrine (NBIX) to $214 from $199 and keeps a Buy rating on the shares. The firm thinks back-to-back record quarters demonstrate Neurocrine’s ability…
Neurocrine price target raised to $215 from $210 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Neurocrine (NBIX) to $215 from $210 and keeps an Overweight rating on the shares. Neurocrine remains a top pick, supported by expectations…
Neurocrine price target raised to $204 from $200 at Needham
Needham raised the firm’s price target on Neurocrine (NBIX) to $204 from $200 and keeps a Buy rating on the shares. The firm expects Neurocrine to trade up following a…
Neurocrine price target raised to $210 from $207 at Piper Sandler
Piper Sandler raised the firm’s price target on Neurocrine (NBIX) to $210 from $207 and keeps an Overweight rating on the shares. The firm notes Neurocrine reported Q2 diluted GAAP…